Vascular, diabetes surge ahead at Abbott:
This article was originally published in Clinica
Abbott Laboratories reported a 14.4% increase in sales of medical products in the fourth quarter, with its vascular devices and diabetes care units providing much of the impetus. The company did not disclose total medical product sales, but said diabetes care was up by 71% to $242m in the quarter, helped by the purchase of TheraSense. Vascular device sales rose by 12% to $60m. Fourth-quarter diagnostic sales rose by 15% to $927m. Group sales rose by 16% to $5.7bn, with earnings up 3% to $975m. Full-year sales and earnings were $20bn (+14%) and $3.2bn (+18%), respectively.
You may also be interested in...
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”